| Title |
Rituximab for rheumatoid arthritis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2015
|
| DOI | 10.1002/14651858.cd007356.pub2 |
| Pubmed ID | |
| Authors |
Maria Angeles Lopez‐Olivo, Matxalen Amezaga Urruela, Lynda McGahan, Eduardo N Pollono, Maria E Suarez‐Almazor |
| Abstract |
Rituximab is a selective, B-cell depleting, biologic agent for treating refractory rheumatoid arthritis (RA). It is a chimeric monoclonal antibody targeted against CD 20 that is promoted as therapy for patients who fail to respond to other biologics. There is evidence to suggest that rituximab is effective and well tolerated when used in combination with methotrexate for RA. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 9 | 50% |
| United Kingdom | 1 | 6% |
| El Salvador | 1 | 6% |
| Unknown | 7 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 72% |
| Practitioners (doctors, other healthcare professionals) | 5 | 28% |
Mendeley readers
The data shown below were compiled from readership statistics for 233 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | <1% |
| Sri Lanka | 1 | <1% |
| South Africa | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 229 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 47 | 20% |
| Student > Ph. D. Student | 31 | 13% |
| Student > Bachelor | 24 | 10% |
| Researcher | 18 | 8% |
| Other | 17 | 7% |
| Other | 41 | 18% |
| Unknown | 55 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 89 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 9% |
| Biochemistry, Genetics and Molecular Biology | 14 | 6% |
| Psychology | 14 | 6% |
| Nursing and Health Professions | 12 | 5% |
| Other | 21 | 9% |
| Unknown | 63 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#2,607,522
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#5,196
of 11,842 outputs
Outputs of similar age
#35,328
of 360,326 outputs
Outputs of similar age from Cochrane database of systematic reviews
#116
of 286 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,326 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 286 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.